PeptideEmergingAnti-inflammatory
ARA-290 (Cibinetide)
EPO-derived peptide (cibinetide)
Also known as ARA-290
Typical dose
2–4 mg
once daily · SubQ
Half-life
short
What is ARA-290 (Cibinetide)?
Non-erythropoietic EPO-derived peptide studied for neuropathy and inflammation.
How ARA-290 (Cibinetide) works
An 11-amino-acid peptide from the tertiary structure of erythropoietin; activates the innate repair receptor (EPOR/βcR) to reduce inflammation and protect tissue — WITHOUT EPO's blood-thickening effect.
Benefits & uses
- Neuropathic pain relief (studied, long-lasting)
- Anti-inflammatory / tissue-protective
- Studied for sarcoidosis/diabetic neuropathy
- Does NOT raise red blood cells (unlike EPO)
Common uses: Neuropathic pain, inflammation, tissue protection (research/trials).
ARA-290 (Cibinetide) dosage
- Typical dose
- Typical: 2–4 mg/day SubQ. 4+ weeks. Non-hematopoietic EPO derivative.
ARA-290 (Cibinetide) half-life
short
ARA-290 (Cibinetide) side effects
- Generally well tolerated in trials
- Injection-site reactions
- Limited long-term data
Warnings & monitoring
- Research peptide (in clinical trials) — not approved. Better-studied than most on this list, but still investigational. See a doctor for neuropathic pain.
Preparation & storage
- Preparation
- Mix a 16 mg vial with 4 mL bac water → 4 mg/mL. A 4 mg dose = 1 mL = 100 units.
- Reconstitution
- Reconstitute a 16 mg vial with 4 mL BAC water → 4 mg/mL. A 4 mg dose = 1 mL = 100 units on a U-100 syringe.
Track ARA-290 (Cibinetide) in Protokol.
Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.
